The study says that BP drugs may improve Kovid-19 survival rate

The study says that BP drugs may improve Kovid-19 survival rate

Let’s Start this Interesting Article Shared on

New Delhi: The drug Kovid-19 for hypertension can improve survival rates, and according to one study, may reduce the severity of novel coronavirus infections, especially in patients with hypertension.
Researchers at the University of East Anglia (UEA) in Britain studied 28,000 patients taking antihypertensives – a class of drugs used to treat hypertension or high blood pressure.
The study, published in Current Atherosclerosis Reports, found reduced risk of severe Kovid-19 disease and death for hypertensive patients taking angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs).
“We know that heart disease patients are at risk of severe Kovid-19 infection,” said principal researcher Vasilios Vasiliou of the UEA’s Norwich Medical School.
“But at the onset of the epidemic, there was concern that specific medications for hypertension may be associated with poor outcomes for Kovid-19 patients,” Vasiliou said.
Researchers at Norfolk and Norwich University Hospital, analyzed what the effect of these drugs is for people with Kovid-19.
They studied outcomes for patients taking antihypertensives, specifically to see what they call ‘severe’ outcomes as being admitted to intensive care or placed on ventilators, and death.
The team analyzed data from Kovid-19 and 19 studies related to ACOE and ARB drugs. The researchers noted that their meta-analysis involved more than 28,000 patients and is the largest and most detailed study ever conducted.
They compared data from Kovid-19 patients who were taking ACEi or ARB medications with those who were not focused on whether they experienced ‘significant’ events and deaths.
“We found that one-third of Kovid-19 patients with hypertension and a quarter of patients overall were taking ACEE / ARB. This is likely due to an increased risk of infection in patients with co-morbidities such as cardiovascular diseases, hypertension, and diabetes. , ”Said Vassiliou.
“But the really important thing that we showed was that there is no evidence that these drugs can increase the severity of Kovid-19 or the risk of death,” he said.
In contrast, the researchers found that there was a significantly lower risk of death and significant consequences, so they might actually play a protective role – especially in hypertensive patients.
According to the study, Kovid-19 patients with hypertension who were taking ACEi / ARB medications were 0.67 times less likely to have serious or fatal outcomes than those not taking these drugs.
“Our research provides sufficient evidence to recommend continued use of these drugs if patients were already taking them,” Vasiliou said.
“However, we have not been able to find that introducing such pills in patients with Kovid-19 may improve their prognosis, as the mechanism of action may be different,” he said.


Leave a Reply

Your email address will not be published. Required fields are marked *